Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Genzyme, a Sanofi Company is the lead sponsor of 8 current clinical trials in our UK, USA, China, India and Ireland registers. 5 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Avalglucosidase alfa, Alglucosidase alfa and Fitusiran. The most-studied condition is Glycogen Storage Disease Type II.

Company profiles on this site (news, sites, medicines, approvals): Sanofi Ireland (IE) →Sanofi SA (FR) →

ClinicalTrials.gov trials by status

Recruiting563%
Active, closed338%

Trials by phase

Observational450%
Phase 2225%
Phase 3113%
Phase 4113%

Clinical trials sponsored by Genzyme, a Sanofi Company

8 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Pompe Disease Registry Protocol NCT00231400 · Glycogen Storage Disease Type II, Pompe Disease	Observational	Recruiting	2004-09	UK, USA, India, China
Fabry Disease Registry & Pregnancy Sub-registry NCT00196742 · Fabry Disease	Observational	Recruiting	2001-07	UK, USA, India, China
Pompe Pregnancy Sub-Registry NCT00567073 · Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency	Observational	Recruiting	2007-06	UK, USA
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry NCT00358943 · ClinicalTrials.gov ↗ · Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease	Observational	Recruiting	1991-04	UK, USA, India, China
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD NCT06666413 · ClinicalTrials.gov ↗ · Glycogen Storage Disease Type II, Pompe's Disease Drug: Avalglucosidase alfa	Phase 4	Recruiting	2025-05	China
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX NCT03754790 · ClinicalTrials.gov ↗ · Hemophilia Drug: Fitusiran	Phase 3	Active, closed	2019-01	Ireland, UK, USA, India, China
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension NCT02843035 · ClinicalTrials.gov ↗ · Gaucher Disease Type 1, Gaucher Disease Type 3 Drugs: Imiglucerase, Venglustat	Phase 2	Active, closed	2017-01	UK, USA
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa NCT03019406 · ClinicalTrials.gov ↗ · Glycogen Storage Disease Type II-Pompe's Disease Drugs: Alglucosidase alfa, Avalglucosidase alfa	Phase 2	Active, closed	2017-10	UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Genzyme, a Sanofi Company trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Avalglucosidase alfa2 Alglucosidase alfa1 Fitusiran1 Imiglucerase1 Venglustat1

Conditions in Genzyme, a Sanofi Company trials

15 conditions

Glycogen Storage Disease Type II2Hemophilia1Pompe Disease1Fabry Disease1Glycogen Storage Disease Type II (GSD-II)1Pompe Disease (Late-onset)1Glycogenesis 2 Acid Maltase Deficiency1Gaucher Disease Type 11Gaucher Disease Type 31Gaucher Disease1Cerebroside Lipidosis Syndrome1Glucocerebrosidase Deficiency Disease1Glucosylceramide Beta-Glucosidase Deficiency Disease1Glycogen Storage Disease Type II-Pompe's Disease1Pompe's Disease1

By trial register

Register	Trials	Recruiting
Clinical trials in UK	7	4
Clinical trials in USA	7	4
Clinical trials in China	5	4
Clinical trials in India	4	3
Clinical trials in Ireland	1	0

A trial with sites in more than one country appears in each of those registers.

Questions about Genzyme, a Sanofi Company trials

How many clinical trials does Genzyme, a Sanofi Company sponsor?

Genzyme, a Sanofi Company is the lead sponsor of 8 current trials on ClinicalTrials.gov in our UK, USA, China, India and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Genzyme, a Sanofi Company trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Genzyme, a Sanofi Company testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Avalglucosidase alfa (2), Alglucosidase alfa (1), Fitusiran (1), Imiglucerase (1) and Venglustat (1). The number in brackets is how many of its trials name each drug.

Does Genzyme, a Sanofi Company have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Genzyme, a Sanofi Company clinical trials